Simultaneous infusion of two incompatible antibiotics: Impact of the choice of infusion device and concomitant simulated fluid volume support on the particulate load and the drug mass flow rates.
Drug incompatibility
ICU
Infusion
Intravenous
Particulate matter
Piperacillin
Vancomycin
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
05 Nov 2022
05 Nov 2022
Historique:
received:
07
07
2022
revised:
16
09
2022
accepted:
17
09
2022
pubmed:
27
9
2022
medline:
21
10
2022
entrez:
26
9
2022
Statut:
ppublish
Résumé
Vancomycin and piperacillin/tazobactam are known to be incompatible. The objectives of the present study were to evaluate the impact of their simultaneous infusion on mass flow rates and particulate load and identify preventive strategies. We assessed both static conditions and a reproduction of an infusion line used in a hospital's critical care unit. A high-performance liquid chromatography/UV diode array system and static and dynamic laser diffraction particle counters were used. The mass flow rates were primarily influenced by the choice of the infusion device and the presence of simulated fluid volume support. Drug incompatibility also appeared to affect vancomycin's mass flow rate, and the dynamic particulate load increased during flow rate changes - especially in the infusion set with a large common volume line and no concomitant simulated fluid volume support. Only discontinuation of the piperacillin/tazobactam infusion was associated with a higher particulate load in the infusion set with a large common volume line and no concomitant simulated fluid volume support. A low common volume line and the use of simulated fluid volume support were associated with smaller fluctuations in the mass flow rate. The clinical risk associated with a higher particulate load must now be assessed.
Identifiants
pubmed: 36162606
pii: S0378-5173(22)00774-8
doi: 10.1016/j.ijpharm.2022.122220
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Piperacillin, Tazobactam Drug Combination
157044-21-8
Piperacillin
X00B0D5O0E
Penicillanic Acid
87-53-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122220Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.